Radiotherapy Protocol of Central Neurocytoma for Resource-limited Settings in the Absence of Official Guidelines: A Case Report and Review of the Literature

Dion Firli Bramantyo; Diaza Okadimar Ariyanto; Krisna Tsaniadi Prihastomo; Rahmi Ardhini; Muhammad Murtadho; Christina Hari Nawangsih Prihharsanti

doi:10.3889/oamjms.2022.10381

Authors

Dion Firli Bramantyo Department of Radiation Oncology, Central General Hospital Dr. Kariadi, Semarang, Indonesia
Diaza Okadimar Ariyanto Department of Medicine, Faculty of Medicine, Diponegoro University, Semarang, Indonesia https://orcid.org/0000-0002-9363-1578
Krisna Tsaniadi Prihastomo Department of Neurosurgery, Central General Hospital Dr. Kariadi, Semarang, Indonesia
Rahmi Ardhini Department of Neurology, Central General Hospital Dr. Kariadi, Semarang, Indonesia
Muhammad Murtadho Department of Medicine, Faculty of Medicine, Diponegoro University, Semarang, Indonesia
Christina Hari Nawangsih Prihharsanti Department of Radiology, Diponegoro University, Semarang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.10381

Keywords:

Neurocytoma, Radiotherapy, Treatment outcome, CNS neoplasm

Abstract

BACKGROUND: Central neurocytoma (CN) is one of the rarest brain tumors which can cause considerable threats to the patient. Studies and trials regarding its treatment are scarce, and no official guidelines are dedicated to this disease. The main principle of treatment generally consists of surgery and radiotherapy. The choice of radiotherapy is divided into conventional fractionated radiotherapy and stereotactic radiosurgery (SRS). However, access to SRS in developing countries such as Indonesia is still limited.

AIM: We report a case delineating the timeline and process of treatment in CN with a review of the literature.

METHODS: We report the case of a 29-year-old woman with a solid inhomogeneous mass (AP 5.63 × CC 5.36 × LL 5.16 cm) in the right ventricle, attached to the septum pellucidum, as displayed on the magnetic resonance imaging (MRI). The patient had been vomiting for the past three weeks and presented with bidirectional horizontal nystagmus.

RESULTS: Cognitive evaluation with Montreal Cognitive Assessment (MoCA-Ina) demonstrated a mild cognitive impairment. Biopsy was performed, and pathology analysis revealed some cells with fibrillary background and some with a honeycomb-like appearance. The immunohistochemistry staining showed positive results with synaptophysin and neuronal nuclear protein. According to the WHO classification of the central nervous system tumors, the profile favored CN Grade II. Subtotal resection (STR) was performed to reduce the tumor mass, which was measured with MRI 2-month post-surgery (AP 4.09 × CC 3.01 × LL 4.13 cm) and then followed by an external radiation program. Using intensity modulated radiation therapy (IMRT), a total dose of 54 Gy was given in 27 fractions, with the average planning target volume of 54.3 Gy. There was a minuscule reduction in tumor mass as seen in post-radiotherapy MRI (AP 4.00 × CC 3.86 × LL 3.63 cm). After the last session and at the 18-month follow-up, the patient did not have any complaints or abnormalities during clinical assessment. Reevaluation using MoCA-Ina showed an improved cognitive function.

CONCLUSIONS: In line with recent evidence, we demonstrated that STR followed by IMRT with the dosage of 54 Gy in 27 fractions was a feasible treatment strategy for CN that resulted in cognitive improvement, with no side effects.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Chen H, Zhou R, Liu J, Tang J. Central neurocytoma. J Clin Neurosci. 2012;19(6):849-53. https://doi.org/10.1016/j.jocn.2011.06.038 PMid:22537657

Hassoun J, Gambarelli D, Grisoli F, Pellet W, Salamon G, Pellissier JF, et al. Central neurocytoma. An electron-microscopic study of two cases. Acta Neuropathol. 1982;56(2):151-6. https://doi.org/10.1007/BF00690587 PMid:7064664

Board WCoTE. World Health Organization Classification of Tumours of the Central Nervous System. 5th ed. Lyon: International Agency for Research on Cancer; 2021.

Wang M, Zhou P, Zhang S, Liu X, Lv L, Wang Z, et al. Clinical features, treatment, and long-term outcomes of central neurocytoma: A 20-year experience at a single center. World Neurosurg. 2018;109:e59-66. https://doi.org/10.1016/j.wneu.2017.09.103 PMid:28958923

Pannullo SC, Julie DA, Chidambaram S, Balogun OD, Formenti SC, Apuzzo ML, et al. Worldwide access to stereotactic radiosurgery. World Neurosurg. 2019;130:608-14. https://doi.org/10.1016/j.wneu.2019.04.031 PMid:31581410

Indonesian Radiation Oncology Society (IROS). Roadmap of Radiotherapy Development in Indonesia. Jakarta: Indonesian Radiation Oncology Society; 2018.

Hallock A, Hamilton B, Ang LC, Tay KY, Meygesi JF, Fisher BJ, et al. Neurocytomas: Long-term experience of a single institution. Neuro Oncol. 2011;13(9):943-9. https://doi.org/10.1093/neuonc/nor074 PMid:21824889

Dutta SW, Kaleem TA, Muller DA, Peterson J, Harrell AC, Quinones-Hinojosa A, et al. Central neurocytoma: Clinical characteristics, patterns of care, and survival. J Clin Neurosci. 2018;53:106-11. https://doi.org/10.1016/j.jocn.2018.04.015 PMid:29685410

Yang I, Ung N, Chung LK, Nagasawa DT, Thill K, Park J, et al. Clinical manifestations of central neurocytoma. Neurosurg Clin N Am. 2015;26(1):5-10. https://doi.org/10.1016/j.nec.2014.09.011 PMid:25432178

Patel DM, Schmidt RF, Liu JK. Update on the diagnosis, pathogenesis, and treatment strategies for central neurocytoma. J Clin Neurosci. 2013;20(9):1193-9. https://doi.org/10.1016/j.jocn.2013.01.001 PMid:23810386

Li J, Recinos PF, Orr BA, Burger PC, Jallo GI, Recinos VR. Papillary tumor of the pineal region in a 15-month-old boy: Case report. J Neurosurg Pediatr. 2011;7(5):534-8. https://doi.org/10.3171/2011.2.PEDS10434 PMid:21529195

Chen CL, Shen CC, Wang J, Lu CH, Lee HT. Central neurocytoma: A clinical, radiological and pathological study of nine cases. Clin Neurol Neurosurg. 2008;110(2):129-36. https://doi.org/10.1016/j.clineuro.2007.09.023 PMid:18022760

Shin JH, Lee HK, Khang SK, Kim DW, Jeong AK, Ahn KJ, et al. Neuronal tumors of the central nervous system: Radiologic findings and pathologic correlation. Radiographics. 2002;22(5):1177-89. https://doi.org/10.1148/radiographics.22.5.g02se051177 PMid:12235346

Jaiswal S, Vij M, Rajput D, Mehrotra A, Jaiswal AK, Srivastava AK, et al. A clinicopathological, immunohistochemical and neuroradiological study of eight patients with central neurocytoma. J Clin Neurosci. 2011;18(3):334-9. https://doi.org/10.1016/j.jocn.2010.05.031 PMid:20869874

Bonney PA, Boettcher LB, Krysiak RS, Fung KM, Sughrue ME. Histology and molecular aspects of central neurocytoma. Neurosurg Clin N Am. 2015;26(1):21-9. https://doi.org/10.1016/j.nec.2014.09.001 PMid:25432180

Kane AJ, Sughrue ME, Rutkowski MJ, Tihan T, Parsa AT. The molecular pathology of central neurocytomas. J Clin Neurosci. 2011;18(1):1-6. https://doi.org/10.1016/j.jocn.2010.06.004 PMid:20884210

Sim FJ, Keyoung HM, Goldman JE, Kim DK, Jung HW, Roy NS, et al. Neurocytoma is a tumor of adult neuronal progenitor cells. J Neurosci. 2006;26(48):12544-55. https://doi.org/10.1523/JNEUROSCI.0829-06.2006 PMid:17135416

Lee SJ, Bui TT, Chen CH, Lagman C, Chung LK, Sidhu S, et al. Central neurocytoma: A review of clinical management and histopathologic features. Brain Tumor Res Treat. 2016;4(2):49-57. https://doi.org/10.14791/btrt.2016.4.2.49 PMid:27867912

Rades D, Schild SE. Treatment recommendations for the various subgroups of neurocytomas. J Neuro Oncol. 2006;77(3):305-9. https://doi.org/10.1007/s11060-005-9047-3 PMid:16575540

Han S, Yang Z, Yang Y, Qi X, Yan C, Yu C. Individual treatment decisions for central neurocytoma. Front Neurol. 2020;11:834. https://doi.org/10.3389/fneur.2020.00834 PMid:32922351

Choudhari KA, Kaliaperumal C, Jain A, Sarkar C, Soo MY, Rades D, et al. Central neurocytoma: A multi-disciplinary review. Br J Neurosurg. 2009;23(6):585-95. https://doi.org/10.3109/02688690903254350 PMid:19922271

Leenstra JL, Rodriguez FJ, Frechette CM, Giannini C, Stafford SL, Pollock BE, et al. Central neurocytoma: Management recommendations based on a 35-year experience. Int J Radiat Oncol Biol Phys. 2007;67(4):1145-54. https://doi.org/10.1016/j.ijrobp.2006.10.018 PMid:17187939

Barani IJ, Raleigh DR, Larson D. The management of central neurocytoma: Radiotherapy. Neurosurg Clin. 2015;26(1):45-56. https://doi.org/10.1016/j.nec.2014.09.014 PMid:25432183

Samhouri L, Meheissen MA, Ibrahimi AK, Al-Mousa A, Zeineddin M, Elkerm Y, et al. Impact of adjuvant radiotherapy in patients with central neurocytoma: A multicentric international analysis. Cancers. 2021;13(17):4308. https://doi.org/10.3390/cancers13174308 PMid:34503124

Garcia RM, Ivan ME, Oh T, Barani I, Parsa AT. Intraventricular neurocytomas: A systematic review of stereotactic radiosurgery and fractionated conventional radiotherapy for residual or recurrent tumors. Clin Neurol Neurosurg. 2014;117:55-64. https://doi.org/10.1016/j.clineuro.2013.11.028 PMid:24438806

Mahavadi AK, Patel PM, Kuchakulla M, Shah AH, Eichberg D, Luther EM, et al. Central neurocytoma treatment modalities: A systematic review assessing the outcomes of combined maximal safe resection and radiotherapy with gross total resection. World Neurosurg. 2020;137:e176-82. https://doi.org/10.1016/j.wneu.2020.01.114 PMid:32001392

Rades D, Schild SE, Ikezaki K, Fehlauer F. Defining the optimal dose of radiation after incomplete resection of central neurocytomas. Int J Radiat Oncol Biol Phys. 2003;55(2):373-7. https://doi.org/10.1016/s0360-3016(02)03918-4 PMid:12527050